News | Left Atrial Appendage (LAA) Occluders | July 07, 2016

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain with cryoICE probe

AtriCure, FROST cryoanalgesia study, William Beaumont Hospital Michigan, cryoICE system

July 7, 2016 — AtriCure Inc. announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, Mich. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.

The design of the trial is a prospective, 3:1 randomized trial including a total of up to 100 patients. The randomization will include up to 75 patients in the treatment arm (intraoperative cryoablation with AtriCure’s cryoICE system plus SOC), and up to 25 patients in the control arm (SOC alone). The study will include patients undergoing unilateral thoracotomy cardiac procedures and will evaluate pain scores and lung function recovery during hospital stay.

The primary objective of the study is to demonstrate that intraoperative intercostal cryoanalgesia in conjunction with SOC provides improved analgesic efficacy and faster, more complete recovery in patients undergoing unilateral thoracotomy cardiac procedures as compared to current SOC. Additional endpoints, such as ICU length of stay, total hospital length of stay, opioid consumption and long-term neurologic recovery will be gathered.

“In my experience, cryoanalgesia appears to result in improved pain management,” said Steven F. Bolling, M.D., professor of cardiac surgery at University of Michigan Medical Center. “Perhaps more importantly, patients seem to extubate sooner and seem to be ready for an earlier discharge. FROST will seek to confirm this effect at multiple cardiac surgery institutions.”

“I have continued to see the benefits of cryoanalgesia therapies in conjunction with minimally invasive mitral valve surgery,” stated Francis Shannon, M.D., cardiothoracic surgeon, Beaumont Health System. “The benefit for patients is quite significant, and I look forward to developing further evidence through participation in the FROST study.”

Participating centers in the study are the William Beaumont Hospital and the University of Michigan Medical Center, as well as Cleveland Clinic Foundation. The coordinating investigators for the FROST study are Shannon and Wei Lau, M.D., at William Beaumont Hospital. Andrea Trescot, M.D., past president of the American Society of Interventional Pain Physicians, is serving as scientific advisor for this trial.

“Today’s pain management options offer relief while patients are hospitalized, but do little to address pain post-discharge,” said Lau, professor of anesthesiology at Oakland University William Beaumont School of Medicine. “We have seen cryoanalgesia control pain and improve recovery post-operatively.”

For more information: www.atricure.com

Related Content

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking